1. Immune response stability to the SARS-CoV-2 mRNA vaccine booster is influenced by differential splicing of HLA genes
- Author
-
Cíntia Barros Santos-Rebouças, Cristina dos Santos Ferreira, Jeane de Souza Nogueira, Otávio José Brustolini, Luiz Gonzaga Paula de Almeida, Alexandra Lehmkuhl Gerber, Ana Paula de Campos Guimarães, Rafael Mina Piergiorge, Cláudio José Struchiner, Luís Cristóvão Porto, and Ana Tereza Ribeiro de Vasconcelos
- Subjects
SARS-CoV-2 ,Vaccine response ,Whole blood transcriptome ,Immune response variability ,Admixed population ,Human leukocyte antigen ,Medicine ,Science - Abstract
Abstract Many molecular mechanisms that lead to the host antibody response to COVID-19 vaccines remain largely unknown. In this study, we used serum antibody detection combined with whole blood RNA-based transcriptome analysis to investigate variability in vaccine response in healthy recipients of a booster (third) dose schedule of the mRNA BNT162b2 vaccine against COVID-19. The cohort was divided into two groups: (1) low-stable individuals, with antibody concentration anti-SARS-CoV IgG S1 below 0.4 percentile at 180 days after boosting vaccination; and (2) high-stable individuals, with antibody values greater than 0.6 percentile of the range in the same period (median 9525 [185–80,000] AU/mL). Differential gene expression, expressed single nucleotide variants and insertions/deletions, differential splicing events, and allelic imbalance were explored to broaden our understanding of the immune response sustenance. Our analysis revealed a differential expression of genes with immunological functions in individuals with low antibody titers, compared to those with higher antibody titers, underscoring the fundamental importance of the innate immune response for boosting immunity. Our findings also provide new insights into the determinants of the immune response variability to the SARS-CoV-2 mRNA vaccine booster, highlighting the significance of differential splicing regulatory mechanisms, mainly concerning HLA alleles, in delineating vaccine immunogenicity.
- Published
- 2024
- Full Text
- View/download PDF